All data are based on the daily closing price as of June 6, 2025
c

Celltrion

068270.KO
119.98 USD
2.45
+2.08%

Overview

Last close
119.98 usd
Market cap
25.12B usd
52 week high
167.56 usd
52 week low
104.55 usd
Target price
164.51 usd

Valuation

P/E
N/A
Forward P/E
35.0877
Price/Sales
9.6957
Price/Book Value
1.9919
Enterprise Value
26.05B usd
EV/Revenue
9.6632
EV/EBITDA
29.9189

Key financials

Revenue TTM
2.70B usd
Gross Profit TTM
1.34B usd
EBITDA TTM
724.06M usd
Earnings per Share
N/A usd
Dividend
0.51 usd
Total assets
14.22B usd
Net debt
N/A usd

About

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. It is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. In addition, the company engages in the wholesale/retail of medicines. The company distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
  • Symbol
    068270.KO
  • Exchange
    KO
  • Isin
    KR7068270008
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Hyong-Gi Kim
  • Headquarter
    Incheon
  • Web site
    https://www.celltrion.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top